Cenforce 200 mg, like other medications containing sildenafil citrate, has a specific mechanism of action in the corpus cavernosum, which is the erectile tissue of the penis. This mechanism of action is primarily related to how sildenafil citrate affects the enzyme phosphodiesterase type 5 (PDE5) and cyclic guanosine monophosphate (cGMP) levels in the body.
Here's a simplified explanation of the mechanism of action:
Relaxation of Smooth Muscle: When a man becomes sexually aroused, nitric oxide (NO) is released in the corpus cavernosum of the penis. Nitric oxide stimulates the production of cyclic guanosine monophosphate (cGMP), which acts as a signaling molecule to relax the smooth muscle cells in the blood vessels of the penis. This relaxation allows blood to flow into the erectile tissue, causing an erection.
Role of PDE5: To maintain an erection, cGMP levels must remain elevated in the penis. However, an enzyme called phosphodiesterase type 5 (PDE5) breaks down cGMP, leading to a decrease in its levels and the subsequent loss of erection. In individuals with erectile dysfunction, this process may occur prematurely, preventing adequate blood flow and resulting in difficulty achieving or maintaining an erection.
Inhibition of PDE5: Sildenafil citrate, the active ingredient in Cenforce 200 mg is a phosphodiesterase type 5 (PDE5) inhibitor. It works by selectively inhibiting the action of PDE5 enzyme, allowing cGMP levels to remain elevated in the corpus cavernosum. This prolonged presence of cGMP promotes relaxation of the smooth muscle cells in the blood vessels of the penis, enhancing blood flow and facilitating the achievement and maintenance of an erection.
By selectively targeting PDE5 and promoting the effects of nitric oxide, sildenafil citrate helps restore erectile function in men with erectile dysfunction, allowing for improved sexual performance. However, it's important to note that sexual stimulation is still required to initiate the physiological processes that lead to an erection.